Basel, Switzerland

Régis Boehringer

USPTO Granted Patents = 1 

Average Co-Inventor Count = 15.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Régis Boehringer in Modified IL-2 Polypeptides

Introduction

Régis Boehringer is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biomedicine, particularly in the development of modified IL-2 polypeptides. His work focuses on innovative treatments for diseases, including cancer.

Latest Patents

Régis Boehringer holds a patent for "Modified IL-2 polypeptides and uses thereof." This patent encompasses modified IL-2 polypeptides, compositions that include these polypeptides, and methods for their production and application. The invention highlights the potential of these modified IL-2 polypeptides in treating cancer by exhibiting preferential binding characteristics to the IL-2 receptor βγ complex over the IL-2 receptor αβγ complex. The molecular weight distribution of these polypeptides is noted to be monodispersed, which is crucial for their effectiveness.

Career Highlights

Régis Boehringer is associated with Bright Peak Therapeutics AG, where he continues to advance his research and innovations. His work is pivotal in the ongoing quest for effective cancer treatments, showcasing his commitment to improving patient outcomes through scientific discovery.

Collaborations

Régis has collaborated with esteemed colleagues such as Vijaya Raghavan Pattabiraman and Roberto Iacone. These partnerships enhance the research and development efforts at Bright Peak Therapeutics AG, fostering a collaborative environment for innovation.

Conclusion

Régis Boehringer's contributions to the field of modified IL-2 polypeptides represent a significant advancement in cancer treatment. His innovative approach and dedication to research continue to inspire progress in biomedicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…